{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:38:57Z","timestamp":1781663937446,"version":"3.54.5"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"SIRIC Lyric","award":["Grant INCa-DGOS-4664"],"award-info":[{"award-number":["Grant INCa-DGOS-4664"]}]},{"name":"Aristot association"},{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Anonymous donation"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0197655","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T13:41:45Z","timestamp":1553175705000},"page":"e0197655","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Activation of the mTOR\/ Akt pathway in thymic epithelial cells derived from thymomas"],"prefix":"10.1371","volume":"14","author":[{"given":"Jean-Michel","family":"Maury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Merveilleux du Vignaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-7655","authenticated-orcid":true,"given":"Gabrielle","family":"Drevet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Zarza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Chalabreysse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Maisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gineys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Dolmazon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Tronc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7923-3127","authenticated-orcid":true,"given":"Caroline","family":"Leroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,3,21]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2007.11.004","article-title":"Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy","volume":"44","author":"WK de Jong","year":"2008","journal-title":"Eur J Cancer"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JTO.0000000000000154","article-title":"ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting","volume":"9","author":"A Marx","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"Suppl 5","key":"ref3","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"N Girard","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their clinical stages","volume":"48","author":"A Masaoka","year":"1981","journal-title":"Cancer"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cncr.10665","article-title":"New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China","volume":"95","author":"G Chen","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0022-5223(96)70265-9","article-title":"Prognostic factors and long-term results after thymoma resection: a series of 307 patients","volume":"112","author":"JF Regnard","year":"1996","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"7","key":"ref7","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/JTO.0000000000000215","article-title":"Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma","volume":"9","author":"N Safieddine","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.bjc.6690773","article-title":"Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience","volume":"81","author":"A Berruti","year":"1999","journal-title":"Br J Cancer"},{"issue":"7","key":"ref9","doi-asserted-by":"crossref","first-page":"S1749","DOI":"10.1097\/JTO.0b013e31821ea5f7","article-title":"Chemotherapy definitions and policies for thymic malignancies","volume":"6","author":"N Girard","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial.","volume":"15","author":"PJ Loehrer Sr","year":"1997","journal-title":"J Clin Oncol"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.21037\/jtd.2016.05.65","article-title":"How large databases may impact clinical practices for rare tumors-postoperative chemotherapy in thymic malignancies","volume":"8","author":"N Girard","year":"2016","journal-title":"Journal of thoracic disease"},{"issue":"15","key":"ref12","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"GL Lemma","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial","volume":"12","author":"PJ Loehrer Sr.","year":"1994","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial","volume":"22","author":"PJ Loehrer Sr.","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00280-011-1690-0","article-title":"Imatinib mesylate in thymic epithelial malignancies","volume":"69","author":"G Palmieri","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"7336","DOI":"10.1038\/srep07336","article-title":"Mutations of epigenetic regulatory genes are common in thymic carcinomas","volume":"4","author":"Y Wang","year":"2014","journal-title":"Scientific reports"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/JTO.0000000000000397","article-title":"Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis","volume":"10","author":"AL Moreira","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"104","key":"ref18","first-page":"re14","article-title":"Bridging with GAPs: receptor communication through RGS proteins.","author":"KM Druey","year":"2001","journal-title":"Science's STKE: signal transduction knowledge environment"},{"issue":"4","key":"ref19","first-page":"876","article-title":"Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer","volume":"7","author":"A Hirano","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ijc.11101","article-title":"Clusters of chromosomal imbalances in thymic epithelial tumours are associated with the WHO classification and the staging system according to Masaoka","volume":"105","author":"R Penzel","year":"2003","journal-title":"Int J Cancer"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood.V95.4.1180.004k14_1180_1187","article-title":"Genetic aberrations common in gastric high-grade large B-cell lymphoma","volume":"95","author":"P Starostik","year":"2000","journal-title":"Blood"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1378\/chest.08-2482","article-title":"Apoptosis-related (survivin, Bcl-2), tumor suppressor gene (p53), proliferation (Ki-67), and non-receptor tyrosine kinase (Src) markers expression and correlation with clinicopathologic variables in 60 thymic neoplasms","volume":"136","author":"T Khoury","year":"2009","journal-title":"Chest"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1038\/cddis.2012.92","article-title":"Copy number aberrations of BCL2 and CDKN2A\/B identified by array-CGH in thymic epithelial tumors","volume":"3","author":"I Petrini","year":"2012","journal-title":"Cell death & disease"},{"issue":"8","key":"ref24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.jtho.2016.04.013","article-title":"PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors","volume":"11","author":"AT Alberobello","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.lungcan.2015.06.014","article-title":"Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy","volume":"89","author":"M Kossai","year":"2015","journal-title":"Lung Cancer"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy","volume":"36","author":"PA Zucali","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"890","DOI":"10.18632\/oncotarget.1015","article-title":"Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses","volume":"4","author":"J Wheler","year":"2013","journal-title":"Oncotarget"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.critrevonc.2016.01.012","article-title":"Thymoma and thymic carcinomas","volume":"99","author":"M Scorsetti","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl 3","key":"ref29","doi-asserted-by":"crossref","first-page":"iii42","DOI":"10.1093\/annonc\/mdw305","article-title":"Crizotinib resistance: implications for therapeutic strategies","volume":"27","author":"I Dagogo-Jack","year":"2016","journal-title":"Ann Oncol"},{"issue":"22","key":"ref30","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"N Girard","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.lungcan.2012.11.015","article-title":"Reproducibility of the WHO classification of thymomas: practical implications","volume":"79","author":"PA Zucali","year":"2013","journal-title":"Lung Cancer"},{"issue":"8","key":"ref32","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-10-1689","article-title":"Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors","volume":"17","author":"M Breinig","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial","volume":"15","author":"A Rajan","year":"2014","journal-title":"The lancet oncology"},{"key":"ref34","article-title":"Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy","author":"PA Zucali","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref35","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/labinvest.2012.115","article-title":"Establishment and characterization of a novel cell line derived from human thymoma AB tumor","volume":"92","author":"Y Gokmen-Polar","year":"2012","journal-title":"Lab Invest"},{"issue":"16","key":"ref36","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/onc.2016.363","article-title":"mTORC1 and mTORC2 in cancer and the tumor microenvironment","volume":"36","author":"LC Kim","year":"2017","journal-title":"Oncogene"},{"issue":"8","key":"ref37","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jtho.2016.06.007","article-title":"Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?","volume":"11","author":"N Girard","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/bjc.2015.425","article-title":"A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas","volume":"114","author":"M Radovich","year":"2016","journal-title":"Br J Cancer"},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The Integrated Genomic Landscape of Thymic Epithelial Tumors","volume":"33","author":"M Radovich","year":"2018","journal-title":"Cancer cell"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0197655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T16:53:38Z","timestamp":1588956818000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0197655"}},"subtitle":[],"editor":[{"given":"Vladimir","family":"Trajkovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,3,21]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0197655","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/317297","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,21]]}}}